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Abstract: Human Papillomavirus (HPV) is strongly associated with the development of 
cervical cancer, and has also been identified in other anogenital cancers such as penile, 
oral, and anal cancers. In regions like Sub Saharan Africa where the prevalence of 
HIV/AIDS is high,   increased rates of HPV infections have also been observed, however 
the effect of HIV/AIDS on the transmission of HPV is not yet well understood.  In this 
study specimens for HIV, HPV testing and pathology were collected from male 
participants and their female partners at a Urology department in Lusaka University 
Teaching Hospital, Zambia. Seventy four samples were collected but only thirty four 
(46%) yielded DNA for HPV testing. HPV detection was done with GP5+/GP6+ PCR, 
followed by DNA sequencing; and HIV detection was done by serology. HPV 16 specific 
primers were used for L1 and LCR variants identification. RESULTS: The overall HIV 
Prevalence was 78.6%, and HPV prevalence among the HIV positive was 68% compared 
to 30% amongst the HIV negative participants. HPV genotype concordance was observed 
in 7(43.8%) couples tested for HPV, and amongst these only 6 had sequence 
similarity.HIV concordance among these HPV concordant couples was 67%.However, 
the role of HIV on HPV type concordance could not be established due to small sample 
size. Variants of HPV 16 in   L1 and LCR region were identified. Six novel HPV 16 
variants with nucleotide exchanges in the LCR region were identified. Five were 
classified as the HPV 16 variant European group, and one as the African group. Two of 
these variants had relatively lower promoter activity, 30% of that of the wild type strain. 
The decreased promoter activity of some HPV 16 variants decreases expression of viral 
oncogenes and may be linked with the development, phenotype and prognosis of the 
cervical lesions in women infected with these kinds of HPV 16 variants. 
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CHAPTER I 
LITERATURE REVIEW 
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Biology of Human Papillomaviruses 
Human Papillomavirus is a small, circular double stranded DNA virus that infects 
cutaneous and mucosal keratinocytes [Graham. 2010]. More than 120 HPV genotypes 
have been identified and categorized based on DNA sequence analysis [de Villiers et al. 
2004]. At least 40 mucosal genotypes infect the genital tract of which 15 types (HPV 16, 
-18,-31,-33,-35,-39,-45,-51,-52,-58,-59,-66, and -68) are categorized as high risk (HR-
HPV) based on their oncogenic potential. The other mucosal HPV types (HPV 6,-11,-40,-
44,-42,-43,-54,-61,-72 and -81 fall in the low risk group and these are associated with 
warts and or low grade intraepithelial lesions [Miura et al. 2010] .  
The prototype genome, HPV 16 is 7904bp and it has three regions, Locus Control Region 
(LCR), the Early genes region and the Late genes region (Figure 1.1). The LCR is a non-
coding region that functions as the major regulatory unit for gene expression. It contains 
a keratin dependent promoter and the origin of replication [Graham. 2010]. The Early 
Open Reading Frames (ORFs) encode proteins expressed early in viral infection and 
these are the transforming proteins E6, E7 and E5; the replication proteins E1, E2 and 
viral assembly protein E4. The late ORFs encode L1, a major capsid protein and L2 
which is a minor capsid protein and these are expressed in highly differentiated cells late 
in infection. These capsid proteins are also important for viral entry into the cell 
[Graham. 2010, McLaughlin-Drubin et al. 2011]. 
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Figure 1.1 Human Papillomavirus (HPV) 16 genome. (E1-E7 early genes, L1-L2 late    
genes: capsid)               
HPV Life cycle 
HPV has tropism for keratinocytes and the initial HPV infection occurs in the basal 
epithelial cells through an abrasion or cut in the epithelial layer (Figure 1.2). While 
specific cell entry receptors have not been identified, it is speculated that HPV uses 
heparin receptors and enters   the cell through claritin coated vesicles [Graham. 2010]. 
Once inside the cell, HPV   replicates extra-chromosomally with the help of cellular 
enzymes. HR-HPVs have well established mechanisms for transforming cells. They 
modify the expression activity of many cellular proteins in order to promote cell 
proliferation; inhibit apoptosis and decrease cell differentiation [McCloskey et al. 2010, 
McLaughlin-Drubin et al. 2011]. They also have mechanisms to suppress the immune 
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system to enable amplification of the viral genome. Oncogenic proteins HR-HPV E6, E7 
and E5 are expressed early during infection in the basal layer which contains stem cells.  
The HPV genome is amplified and shared amongst daughter cells providing a pool of 
HPV genome for every cycle of cell division. The HR-HPV E6 through binding the 
E6AP which is a ubiquitin ligase degrades p53 in a proteasome dependent manner [Jha et 
al. 2010, McLaughlin-Drubin et al. 2011] inhibiting apoptosis or G1 cell cycle arrest.  
HR-HPV forces cells to enter into S phase by expressing HR-HPV E7 that binds the 
 
Figure 1.2 HPV Life cycle: Early Proteins E6, E7 and E5 are expressed in the basal 
cells and as the epithelial cells differentiate the replication proteins E2, E1 and viral 
assembly protein, E4 are expressed. The late proteins L1 and L2 are expressed in 
fully differentiated cells. 
 
hypo-phosphorylated pRb [Banerjee et al. 2011]. Rb family of proteins interact with E2F 
family of proteins at physiological levels to regulate cell cycle. Binding of HR-HPV E7 
to pRb releases E2F which activates the DNA synthesis machinery [Chellappan et al. 
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1991]. The expression level of HR-HPV E7 is closely correlated with the transforming 
potential of the virus, and high levels of HR-HPV E7 mRNA expression have been found 
in oral and cervical cancer biopsy samples [Jha et al. 2010]. The other mechanism that 
HR-HPV E7 uses to maintain viral DNA is by extending the G2 phase through the 
induction of cyclin B1 and cdc2 that accumulate in the cytoplasm of suprabasal cells 
[Banerjee et al. 2011]. McCloskey, R et al have also shown that HR-HPV E7    increases 
cellular proliferation and decrease proliferation through increased expression of 
nucleophosmin nucleolar protein, allowing for increased transcription of viral genome.  
[McCloskey et al. 2010].  
In order to evade the immune system HR-HPV E7 down regulates the expression of 
MHC I on the infected cells to avoid immune surveillance and killing by CD8+Cytolytic 
cells [Heller et al. 2011]. The other protein that enhances transformation of cells by HR-
HPV is the HPV E5. A study showed that mice that were injected with HPV-E5 
developed tumors at a high frequency compared to transgenic mice that had mutations in 
the Epidermal Growth Factor Receptor (EGFR) [Genther Williams et al. 2005b]. This 
was later shown to occur through E5 coupling the  Epidermal Growth Factor  (EGF) 
which  enhances its binding to Epidermal Growth Factor  Receptor (EGFR) thereby,  
driving the cell into S phase [Genther Williams et al. 2005a]. HPV-E5 also functions by 
helping HPV infected cells evade the immune surveillance through down regulation of 
CD1d expression [Miura et al. 2010]. In addition to these functions, HPV E5 also 
promotes anchorage independent growth and it inhibits cell to cell communication 
[Suprynowicz et al. 2010]. Through these process HPV is able to maintain a low copy 
number of viral DNA in the basal cells.  
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When the daughter cells from the basal layer differentiate the HPV DNA in them 
undergoes replication through the expression of HPV E2 and E1 proteins [Graham. 
2010]. These proteins are required for both replication of viral DNA and transcriptional 
regulation [Graham. 2010]. E2 and E1 bind cooperatively to the origin of replication. E1 
is an ATPase helicase, and E2 is responsible for the recognition of origin of replication. 
This combination initiates the replication of DNA genome. E4 is also expressed at this 
stage and is necessary for binding the cytokeratin and blocking the cells in G2/M phase. 
It is the increased expression of E1and E2 that leads to a high viral DNA copy number 
and increased proliferation in stratified epithelial cells [Graham. 2010] causing 
microscopically observed hyperplasia of the cells.  
Late gene proteins L1 and L2 are expressed in the highly differentiated epithelial cells. 
The L1 oncoprotein has been shown to be   highly immunogenic [Christensen and 
Kreider. 1990] and is expressed in fully differentiated cells where there is less immune 
surveillance, so this could be another mechanism for the virus to evade the immune 
system. These late proteins form the viral capsid and are important for viral assembly and 
later for attachment during infection [Hindmarsh and Laimins. 2007]. The viral capsid 
has 72 capsomeres, each of which is made of L1 pentameres associated with L2 or more 
L2 proteins [Pittayakhajonwut and Angeletti. 2008]. The infectious mature virions are 
released as the fully differentiated epithelial cells peel off and can re-infect the 
neighboring cells or be transmitted to the next host. 
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Epidemiology of HPV 
Persistent infection with the mucosal alpha Human Papillomavirus eventually leads to the 
development of either benign or malignant tumors [Coutlee et al. 1995, Hindmarsh and 
Laimins. 2007]. Studies have shown that high risk alpha-human papillomavirus (HR-
HPV) is the etiological agent for more than 90% of cervical cancer, the second most 
common female cancer globally [Munoz et al. 2003, Walboomers et al. 1999, zur 
Hausen. 1996]. Penile cancer though of rare occurrence, has also been associated with 
HPV. HPV accounts for about  40% of penile  cancers  with HPV 16 having the highest 
prevalence [Guimaraes et al. 2011, Ng'andwe et al. 2007, Silva et al. 2011].HR-HPV is 
also associated with other anogenital and head and neck cancers[Arany et al. 1998, 
Graham. 2010, Miura et al. 2010, Smith et al. 2004]. 
HPV and HIV 
Most individuals get exposed  to HPV over their lifetime,  but the majority are able to 
clear the virus through the induction of the immune system [Rowhani-Rahbar et al. 2007, 
Stanley. 2010]. Amongst individuals who are immunosuppressed, HPV infection  persists 
because of the inability of the immune system to clear the virus [Arany et al. 1998, Wang 
et al. 2011]. The immune response in HIV infected individuals is compromised and this 
predisposes them  to other infectious diseases including HPV. Several studies have 
reported increased prevalence of HPV infections among people infected with  HIV 
compared to those who are HIV negative [Arany et al. 1998, Hawes et al. 2006, Minkoff 
et al. 2001] and the rates of HPV infection   have also been shown to increase among 
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individuals  with  low CD4+ cells    and high HIV viral load[Mbulawa et al. 2010, Wang 
et al. 2011]. 
 In Sub Saharan Africa,   the region with highest rates  of HIV infection, increased rates 
of HPV infection and HPV associated diseases have also been reported.  [Desruisseau et 
al. 2009, Louie et al. 2009, Ng'andwe et al. 2007]. In 2009 the incidence  rates of 
Invasive Cervical Carcinoma  in Sub Saharan Africa was 31.0 per 100,000 women, which 
was the highest in the world [Louie et al. 2009]. The mechanism of HIV and HPV 
association is not well understood. However, considering that cellular immunity is very 
important in  viral clearance, it is probable that the  loss in control of T cell distribution  
caused by HIV infection  coupled with the down regulation of MHC I and CD1d by HPV   
helps to establish a persistent HPV infection. The other factor could  be the route of 
transmission. Both HIV and HPV are   sexually transmitted, so if proper preventive 
measures are not observed then one can get both infections  at the same time.  
 
HPV 16 Variants 
The distribution of HPV genotypes differ by geographical regions, but HPV16 is the most 
prevalent high-risk genotype strongly associated with cervical cancer and accounts for 
about 50% of all cases globally [Kammer et al. 2000]. HPV16 has also been identified in 
anogenital cancers as well as head and neck carcinomas [Grulich et al. 2010, Muñoz et al. 
2006]. HPV 16 is well studied because of its clinical significance and HPV 16 variants 
have been characterized. An HPV variant is defined as one that differs from other viruses 
of the same genotype by up to 2% in conserved regions of the genome, such as E1 or L1 
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ORFs, and by up to 5% in the LCR [Kammer et al. 2000]. HPV16 variants have varying 
degree of association with progression to cervical cancer, and this might explain why 
some people with HPV 16 progress to cancer faster than others. Differences in HPV 16 
variants may be due to differences in transcriptional regulation by the virus or by 
biological properties of proteins encoded by HPV 16 variants. Studies and phylogenetic 
characterization of the conserved regions and LCR of HPV16 from cervical samples 
demonstrated that HPV16 variants can be divided into six distinct phylogenetic clusters 
distributed roughly by geographical regions; the European (E) group, two African (Af) 
groups, the Asian (As), Asian American (AA) and North American (NA) variants [Pande 
et al. 2008, Zuna et al. 2009, Zuna et al. 2009]. These variants also differ by oncogenic 
potential and epidemiologic studies indicate that non-European variants have increased 
oncogenic potential [Kammer et al. 2000]. 
L1 gene encodes the major capsid protein L1 and this protein is highly immunogenic 
[Murata et al. 2009]. Variations in the L1 region have been isolated from clinical samples 
and some of these have mutations that cause a conformational change within epitopes 
needed for binding the neutralizing antibodies [Pande et al. 2008]. These mutants are then 
able to resist clearance by antibodies mounted against the major HPV strain. Changes in 
the L1 region can also affect the ability of L1 to form Virus like particles. 
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Introduction   
Human Papillomaviruses are small non-enveloped, circular double stranded DNA 
molecules of about 7900bp in icosahedral capsids [Lowe et al. 2008]. The HPV genome 
encodes for eight proteins; early protein -E1, E2, E4, E5, E6 and E7 and late proteins L1 
and L2.  L1 forms the major capsid protein which is also important for the entry of the 
virus into the cell. HPVs form a diverse  group with more than 100 types, at least 40 of 
these infect the   genital area , with 15 types (HPV16, -18, -31, -33, -35, -39,-45, -51, -52, 
-56, -58, -59, -66, -68, and -73) classified as high risk HPV [Munoz et al. 2003] 
Human Papillomavirus is strongly associated with development of cervical cancer.  Most 
individuals infected with human Papillomavirus clear the infection without developing 
any recognizable symptoms [Rowhani-Rahbar et al. 2007, Stanley. 2010]. Progression to 
cancer is dependent on both host and viral factors. Viral type is one such viral factor. 
Infection with low risk HPV types can produce benign tumors or genital warts. However, 
persistent infection with high risk alpha human Papillomaviruses (HR-HPV) is the 
necessary cause for cervical cancer and other anogenital cancers [Chaturvedi. 2010]. 
 The greatest antibody response in people infected with HPV are to the L1 protein 
[Murata et al. 2009], and the binding site for these type specific antibodies is a 
conformational epitope. In order to lessen the immune response, HPV produces   L1 
proteins in small quantities; later in the cycle and in   terminally differentiated epithelial 
cells [Pittayakhajonwut and Angeletti. 2010]. The other possible mechanism that HPV 
can use to promote positive selection is to undergo mutation in the highly immunogenic 
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L1 protein, thus avoiding neutralization by the type specific antibodies that an individual 
could have developed either through vaccination or prior infection. 
The immune status of the host plays an important role in the progression of the disease, 
and one study has shown an association between HIV negativity and HPV clearance 
[Banura et al. 2010]. While the specific mechanisms associated with increased 
susceptibility to HPV of HIV positive individuals are not fully understood, it is likely that 
the impaired cell mediated and humoral immunity present an advantage to progression of 
HPV infection toward a malignant state. HIV infection dramatically lowers or shifts 
populations of memory and effector T cells, effectively removing immune surveillance of 
newly forming neoplastic lesions. Report from one study has also shown that HIV has an 
influence in the expression of HPV genes [Arany et al. 1998]. 
Genotype specific HPV neutralizing antibodies are necessary for the prevention of 
infections and if an infection occurs, cell mediated immune response is needed to clear 
the infection but this immunity is impaired in HIV infected individuals [Stahl-Hennig et 
al. 2009]. Several studies have shown that there is high HPV prevalence among HIV 
infected people [Chaturvedi. 2010, Palefsky. 2009], and the association of HPV and HIV 
with progression of genital lesions to cancer has been well established [Firnhaber et al. 
2010, Silverberg et al. 2002]. The higher prevalence of HPV related cancers amongst 
HIV infected individuals could also be due in part to availability of HAART which 
prolongs the life expectancy, thereby increasing risk for progression into cancer.  
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Sub-Saharan Africa has highest rates of HIV/AIDS and in 2008 it accounted for 67% of 
HIV infections worldwide [UNAIDS. 2009]. High rates of HPV   infection have been 
reported   from studies in this region especially among HIV positive individuals [Banura 
et al. 2010, Luchters et al. 2010, Moodley et al. 2009]. In Zambia, the University 
Teaching Hospital has reported HPV related cancer of the cervix as the leading cancer, 
representing 29% of all cancers seen in the hospital over the last 10 years [Bowa et al. 
2009]. 
Persistent HR-HPV infections have also been associated with the development of penile 
cancer [Arany et al. 1998, Rombaldi et al. 2006], and like other HPV related cancers, the 
incidents of penile cancer are also higher among the HIV positive individuals. In the 
United States, HIV positive males have a 5-6 fold increased risk of developing penile 
cancer [Chaturvedi. 2010]. 
HR-HPV 16 type accounts for most cases of HPV related cervical cancers [Moodley et 
al. 2009] and HPV 16 variants based on sequence variation of the L1, L2, E6 and LCR 
have been defined. These HPV 16 variants can be divided into six different phylogenetic 
clusters: European (E) group, Asian (As), two African (Af) groups, Asian-American 
(AA), and North American (NA) group [Wheeler et al. 1997, Yamada et al. 1997]. HPV 
16 isolates are defined as variants when the nucleotide sequence differs by up to 2% in 
conserved regions of the genome, such as E1 or L1 ORFs, and by up to 5% in the LCR 
[Kammer et al. 2000]. These HPV 16 variants show differences   in their biological and 
biochemical properties. Epidemiologic studies have shown that non European HPV 16 
14 
 
variants have a higher oncogenic potential, with Asian-American being the most 
oncogenic [Kammer et al. 2000]. 
The purpose of this study is to look at the effect of the two variables; HIV and genital 
lesions on the HPV genotype concordance amongst heterosexual couples. We also 
wanted to analyze HPV 16 sequence variations in the L1 and LCR regions to determine 
the prevalence and novelty of HPV 16 variants. Understanding the effects of HIV and 
genital lesions on HPV genotype concordance and the knowledge of the circulating HPV 
16 variants in the population will help in designing prevention strategies. 
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COUPLES 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
Study Participants  
The study participants were recruited at the University Teaching Hospital Lusaka, 
Zambia (in collaboration with Dr. Kasonde Bowa). Individuals seen at the Urology clinic 
with any pathological penile lesion were recruited into the study. A penile lesion is 
defined as a macroscopically visible, acquired non-traumatic lesion on the glands, 
prepuce or penile shaft. For participation in the study, the index patient had to have a 
spouse or a regular female partner. A regular female partner is defined as someone with 
whom the index patient had regular sexual contact in the last six months. Three male 
participants, who were asymptomatic, were recruited into the study with their partners to 
serve as controls. The index patient and his partner were both recruited, and only 
included in the study after giving informed written consent. 
Sample Collection 
Two biopsy samples were collected from male partners; one sample was used for 
pathology evaluation and the other for HPV testing. The pathology results were classified 
as normal, benign/wart, malignant, ulcer or infection. The female participants had a 
cervico-vaginal lavage (CVL) and pap smear taken. The Pap smear was   examined by a 
local consultant pathologist and the results were based on the Bethesda System for 
reporting cervical or vaginal cytological diagnoses [Apgar et al. 2003]. The CVL samples 
were treated with Qiagen DNeasy detergent solution, frozen at   minus 20
0
C, then 
shipped together with the penile lesion HPV samples to Nebraska Center for Virology at 
the University of Nebraska-Lincoln (UNL) for HPV testing. 
17 
 
HPV DNA detection and genotyping 
DNA extraction was done using the Qiagen Blood and Tissue extraction kit (DNEASY). 
HPV detection was done using HPV consensus primers GP5+ (5’-TTTGTTACTGT 
GGTAGATACTAC-3’) and GP6+ (5’-GAAAAATAAACTGTAAATCATATTC-3’) 
[Ng'andwe et al. 2007]   that amplify 150bp of L1 region. Beta actin amplification was 
done in all the samples as an internal quality control for the extracted DNA. Samples 
positive for HPV 16 were further amplified with   HPV 16 specific primers for L1; L1 
nt6155 (5’-GTCGGTACCCCATGTACCAATGTTGCAG3’) and L1 nt7782 (5’CTACC 
CGGGGTGACATTTAGTTGGC CT-3’) that amplify 1597 bp of the L1 region and part 
of the LCR. The   reaction mixture of 50µl contained: 1 µl of the template DNA, 1.5mM 
Mglc2, 0.2mM deoxynucleotide triphosphate (dNTP), 0.5µM each of the primers and 
1.25U Promega Go Taq® DNA Polymerase (Promega Corporation WI, USA). PCR 
conditions were set at: 94
0
C for 5 minutes followed by 30 cycles of (95
0
C for 30s, 62
0
C 
for 1 min,72
0
C for 90s) and 72
0
C for 10 min. All amplifications included a positive 
control of HPV 16 DNA and a negative control of nuclease  free water.  
PCR products were separated either  by  2%(for 150bp product and 0.7% ( for 1597bp 
product) agarose gel using 1X Tris Acetate Ethylene-diamine-tetraacetic acid (TAE) 
buffer. At the end of electrophoresis, the gel was stained with ethidium bromide and 
visualized under ultraviolet light. The bands from positive samples were excised and 
isolated using the Qia quick gel extraction kit(Qiagen). The extracted DNA was cloned 
into pGEMT- Easy vector system (Promega Corporation WI, USA) by mixing 5ul ligase 
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with 50ng pGMET-Easy vector  and 7.5ng DNA template. These were incubated at 40C 
overnight for maximum cloning efficiency.   
 
The plasmids were transformed into DH5 alpha competent cells (100µl/plate) followed 
by incubation at 37
0
C overnight in LBA plates containing 100μl (20 mg/ml) of isopropyl-
beta-D-thiogalactopyranoside (IPTG) and 20μl (50 mg/ml) of 5-bromo-4-chloro-3-
indolyl-beta-D-galactopyranoside (X-GAL).This  procedure allowed for selection of  
clones  using blue white selection. Two white colonies  were picked and cultured 
overnight  at 37
0
C in  5ml LB/Ampicillin(100ug/ml).The plasmid DNA was extracted 
using QIAprep Spin Miniprep Kit (QIAGEN Inc. CA, USA). To check for proper insert 
in  the plasmid DNA, EcorI was used to digest 1µL of the DNA, and this was run on the   
agarose gel. The  samples with inserts were sent for DNA sequencing and the  BLAST 
alignment software (http://blast.ncbi.nlm.nih.gov/) was used to identify  the genotypes 
and  KALIGN software  was used to align variants  sequences. (http://www.ebi.ac.uk/)  
Two independent PCR amplifications, cloning, and sequencing steps were performed to 
make certain that identified L1 sequence variants were not the result of Taq-derived mis-
incorporations,  
HIV testing 
Blood samples were collected from participants who  gave consent for  HIV testing  and 
diagnosis was done  in a designated HIV laboratory following the Zambia Ministry of 
Health testing protocol. The technicians doing HIV testing were  blinded from the HPV 
results and diagnosis and those doing HPV testing were blinded to the HIV status, until 
the testing was complete in both labs. 
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Results  
Eighty eight individuals from ages 18 years to 66 years  were initially recruited in the 
study, but fourteen  did not meet the study  inclusion criteria and were excluded. Reasons 
for exclusion were death of the partner, penile amputation and decline to 
participate(Figure 3.1). The average age  for the remaining seventy four participants  was 
36(SD+/- 10) years for males  while the average female  age was 30(SD +/-8) years. 
 
Figure 3.1 Summary of study Participants 
 
Sixty one  participants (82%) agreed to test for HIV. Among these, 48(78.6%) were HIV 
positive, and ten (21.4%) were HIV negative (Figure 3.1).  
The penile pathology results were categorized into 4 groups; these were penile cancer, 
penile warts/benign tumor, penile ulcer/infection, and normal. The most common penile 
lesions were penile warts/benign tumor 20(54%) followed by penile cancer 9(24%). 
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Twenty four (65%)  female partners had premalignant lesions  and two (5.4%) had 
invasive cervical cancer. Nine (24.3%) females were negative for intraepithelial 
lesion(NIL) and of these two had cervical infections other than HPV. Two(5.4%) had  an 
indeterminate result- loss of material or failure of processing(Figure 3.2). 
               
a) Female lesions, n=37  b)Male Lesions, n=37 
Figure 3.2 Distribution of genital Lesions. NIL-Negative for intraepitheial 
lesions.Indeterminate-loss of material or failure of processing.Premalignant 
category included cervical intraepithelial neoplasia(CIN) 1-3.                           
 
HIV and risk of cervical and penile lesions 
HPV infection was closely associated with HIV positivity. Sixty eight (68%) percent of 
those who were HPV positive were also HIV positive compared to thirty (30%) percent  
being HIV negative. (Figure 3.3) 
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Figure 3.3 HPV prevalence by HIV status, N =34.  HPV infection was closely 
associated with HIV positivity. Relative risk ratio 0.963 [ 0.89 1.036] 
 
The HIV positive  females were more likely to develop premalignant or malignant 
lesions, 69%, compared to HIV negative females at 3.8% (p=0.095).The risk of penile 
lesions amongst HIV positive individuals was 75% compared to 14.2%, hence overall 
HIV positive individuals were  eight times more likely to develop cervical or penile 
lesions than negative  individuals.(Table 3.1) 
Table 3.1 Association of HIV status and genital lesions. HIV positive individuals are 
more likely to have cervical or penile lesions compared to those who are HIV 
negative. 
 Number of lesions,(%) 
HIV status All p-value Females p-value males p-value 
Positive 39(72) 0.137 18(69) 0.095 21(75) 0.463 
Negative 5(9)  1(3.8)  4(14.2)  
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HPV genotype distribution  
Thirty four individuals (17 couples) were successfully tested for HPV. Out of these only 
one was found to be HPV negative. Genotypes identified in this group included HPVs -
16,-35,-45,-58,-6,-11, and -83.HPV 16 was the most  predominant, accounting for 
18(53%) of  all HPV types identified. (Figure 3.4) 
  
 Figure 3.4 HPV genotype frequencies. The relative distribution of each genotype was determined. 
The x-axis represents the genotype and the y-axis represents the  prevalence. N= 34. 
 
 Male samples genotyped included penile warts/benign tumor (9), penile ulcer/infections 
(2), penile cancer (3) and normal foreskins (3).These were all found to be  HPV infected. 
Penile wart /benign tumor samples were shown to be associated with HPV 16, 6, and  11. 
The three asymptomatic male circumcision samples were all found to be HPV positive. 
These samples had HPV 16(2) and 83(1).Penile ulcer/infection samples were associated 
with HPV 16, 6 and 45. The only penile cancer sample genotyped was identified as HPV 
6. The overall HPV distribution for this group of males was found to be predominated by 
HPV 16 followed by HPV 6  which were 20% and 17% respectively  of male infections. 
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The less frequent HPV genotypes identified were 11, 83 and 45.Among the female 
partners who were HPV genotyped, one was identified to be HPV negative whose male 
partner was HPV positive and diagnosed with penile warts. Genotype frequencies 
observed in female partners were HPV 16 (31%),58 and 11 (6%) each and 45(3%). The 
11 pre-malignant samples were associated with high risk  HPV 16(9) and HPV 58 (2).  
HPV genotype concordance within couples 
Two HPV genotypes were found to be concordantly expressed between both male and 
female partners, HPV 16 and 11.A total of seven couples (43.8%) were found to have 
concordant HPV genotypes. Six couples had HPV 16 and one couple had HPV 11. Since 
the prevalence of HPV 16 was high in this cohort, and most of the couples that  were 
concordant  had HPV 16, we analyzed for  HPV 16 variants concordance  within couples. 
Out of the six couples that were concordant for HPV 16,  only five shared the same HPV 
16 variant. Among the six couples that had HPV sequence similarity concordant couples, 
3 (50%) had  concordant HIV positive results, one  had concordant  HIV negative results, 
and two couples had a discordant HIV results. Most of the male partners (67%) who had 
concordant HPV genotypes with their female partners had a penile lesion. Amongst   the 
eight discordant couples, at least one partner  in  six couples was found to be harboring 
HPV 16. The other two couples had  HPV 58 and 45. Some of the HPV 16  variants 
identified had mutations and we found that some of these mutations were  the same 
among couples as shown in the example, Figure 3.4. 
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Table 3.3 Characterization of HPV genotype concordant couples. AF1- African 1; 
AF2-African 2; E- European.NIL-Negative for intraepitheial lesions.Cervical 
intraepithelial neoplasia(CIN) 1-3 
 
 
HPV L1 VARIANTS 
There were 18 samples that were positive for HPV 16, and sequence analysis of the  L1  
region, showed that  there was variation in HPV 16 amongst these participants. The most 
common HPV 16 variant, African group 1, made up 50% of the variants, the European 
group accounted for 33% while the African 2 variant made up 17% of the HPV 16 
genotype. Some of these variants had mutations and T6313C was the most common  
mutation observed  mainly in all  AF1 group. We also observed T6495C  in 17% of the 
variants. Some mutations were shared amongst  couples indicating a long term evolution 
of the virus. Couple 4 had C6459T mutation while couple 6 had T6495C mutation. 
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Discussion 
In 2002, the number of new cervical cancer cases in developing countries was estimated 
at about 490,000 and 274,000 women died from invasive cancer of the uterine cervix 
induced by oncogenic genotypes of human Papillomavirus (HPV).In Zambia cancer of 
the cervix is the most common cancer with an incidence of 67.1 per 100,000 per 
year[Bowa et al. 2009, Parham et al. 2006]. 
Though the study sample is small some interesting discussion points are raised by the 
study. There was a high percentage of cervical lesions in the study cohort (70.4%), much 
higher than that observed in women with partners having penile lesions [Bleeker et al. 
2002]. The study found a high proportion of premalignant and malignant lesions in 
female partners, which could be associated with the high prevalence of HIV and 
oncogenic high risk  HPV subtypes,  as shown by this study and  other studies in Zambia 
[Bleeker et al. 2002, Sahasrabuddhe et al. 2007].The HIV infection suppresses cellular 
immunity which is useful in clearance of HPV infection. Our study has shown that HIV 
positive individuals are at least twice as likely to be infected with HPV, and the 
prevalence of High Risk (HR) types in HIV positive is twice as likely as the LR types. 
Previous studies have also shown that HPV infection is high in the general population 
and even higher in HIV infected populations[Bleeker et al. 2002, Sahasrabuddhe et al. 
2007]. 
The HIV prevalence was  78.6% which  is much higher than the population prevalence of 
14.3%.  However, the high HPV co-infection rate could indicate both high risk behavior 
and high likelihood  of HIV infection or simply due to a selection of a population with 
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much higher risk of infection, though a larger study would be needed to confirm this. Our 
study didn’t establish the relationship between HIV status and HPV genotype 
concordance, and this could be due to small sample size, therefore more samples will 
need to be done. The presence of penile lesions seemed to increase the likelihood of   a 
couple being HPV concordant. This study has also shown that heterosexual couples with 
active HPV infections can harbor identical or different HPV genotypes at any given time 
point. Females were found to harbor HR  types at a greater rate than their male 
counterparts. These differences may be as a result of the site  of specimen collection.HR 
HPVs would present a greater likely hood of establishing a persistent infection in the 
female genital tract,58.8% compared to 17.6% in  males whereas male penile warts are 
likely to harbor LR HPV genotype,35.3% compared with 5.9% in females.  
The difference in HPV genotype distribution could  imply that despite repeated exposure 
to LR HPV genotype harbored in a male wart, the female genital tract  clears the LR but 
maintains dominant HR infection. Other than  clearance of the virus, the presence of 
discordant HPV genotypes  amongst couples   could also be due to multiple concurrent 
partners, but because not enough demographic data was collected,  the next phase will 
address such questions. 
HPV 16  was found to be the predominant type accounting for 52%  of all HPV 
genotypes identified which is expected for an HIV endemic location .Previous studies 
have also reported high prevalence of oncogenic strains of HPV   in Sub Saharan Africa 
where the rates of HIV are high [Baay et al. 2004, Firnhaber et al. 2010, Smith et al. 
2007]. Interestingly, the control penile samples  taken from asymptomatic adult male 
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circumcisions were found to  be infected with HPV 16 and 83.Two of these controls were 
further found to have concordant genotypes with the female partners suggesting that in 
the absence of penile tissue abnormality  it is likely  couples will harbor  the same 
dominant HPV genotype.  The HPV 16 isolated from this group was found to have L1 
variation. We observed AF1, European and AF2 variants in this population. Mutations at 
nt 6495, 6313 and 6459 were observed and this is indicative of the hyper-variability of L1 
gene. The nt 6459 and 6495 are in the exterior loop of L1 protein, which is highly 
immunogenic. Mutations in this region  may be important for viral fitness  as they may 
cause conformational changes within epitopes  needed for binding neutralizing 
antibodies. 
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Abstract 
HPV 16 is the most prevalent high-risk viral genotype associated with cervical cancer. 
Six distinct phylogenetic clusters of HPVs have been identified and are distributed 
differently within five continents. HPV 16 DNA extracted from cervico-lavage samples 
from women with normal pap smears and the LCR regions were amplified in triplicate, 
cloned, sequenced, and analyzed. A total of 11 recovered HPV16 positive samples 
[Ng’andwe et al. (2007): BMC Infect Dis 7:77] were analyzed for sequence variation. 
The HPV16 LCR variants were assessed for promoter activity by use of the luciferase 
reporter gene. Six novel HPV 16 variants with nucleotide exchanges in the LCR region 
were identified. Five were classified as the HPV 16 variant European group, and one as 
the African group. Two of these variants had relatively lower promoter activity, 30% of 
that of the wild type strain. The decreased promoter activity of some HPV 16 variants 
decrease expression of viral oncogenes and may be linked with the development, 
phenotype and prognosis of the cervical lesions in women infected with these kinds of 
HPV 16 variants 
 
Introduction 
Epidemiological and molecular studies have demonstrated that high-risk alpha-human 
papillomavirus (HPV) is the etiological agent responsible for the majority of cervical 
cancers, the second most common female cancer globally [Walboomers et al., 1999; zur 
Hausen, 2000; Munoz et al., 2003]. So far, more than 120 different HPV types have been 
identified and characterized on the basis of DNA sequence analysis[de Villiers et al., 
2004]. At least 40 HPV types infect the genital area, of which 15 types (HPV16, -18, -31, 
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-33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68, and-73) are classified as high-risk 
because of their oncogenic potential [Munoz et al., 2003]. HPV16 is the most prevalent 
high-risk type associated strongly with cervical cancer and accounts for about 50–60% of 
all cases of cervical cancer globally [Clifford et al., 2003].HPV16 has also been found in 
multiple cancers of the anus, vulva, vagina, and penis, as well as a subset of head and 
neck carcinomas [Koskinen et al., 2003; Ritchie et al., 2003].Although HPV genomes 
have been thought to be rather evolutionarily stable, nucleotide changes have been 
increasingly observed in clinical isolates. An HPV variant is defined as one that differs 
from other viruses of the same type by up to 2% in conserved regions of the genome, 
such as E1 or L1 ORFs, and by up to 5% in the LCR [Kammer et al., 2000]. HPV16 has 
been examined in great detail due to its medical importance, and numerous HPV16 
variants have been identified. Studies and phylogenetic characterization of the LCR of 
HPV16 from worldwide cervical samples demonstrated that HPV16 variants can be 
divided into six distinct phylogenetic clusters distributed differently across the five 
continents: the European (E) group, two African (Af) groups, the Asian (As), Asian 
American (AA), and North American (NA) variants [Wheeler et al., 1997; Yamada et al., 
1997]. Different HPV16 variants exhibit differences in their biological and biochemical 
properties. Epidemiologic studies indicate that non-European variants of HPV16 exhibit 
increased oncogenicity, specifically members of the Asian-American class AA [Kammer 
et al., 2000]. 
The early proteins of high-risk HPV, E6 and E7, play an important role in the 
carcinogenesis of human cells. They bind with and inhibit the function of the tumor 
suppressors p53 and pRb respectively [Dyson et al., 1989; Scheffner et al., 1990]. The 
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high-risk E6 and E7 protein also modify the expression activity of many cellular proteins 
in order to promote cell proliferation [Underbrink et al., 2008]. The expression level of 
HPV E7 is closely correlated with the transforming potential of the virus, and high levels 
of HPV E7 mRNA expression have been found in oral and cervical cancer biopsy 
specimens [Liu et al., 1995].Recently, studies have shown that HPV16 E5 also plays a 
critical role in mechanism of tumorigenesis [Hu et al., 2009]. The E1 and E2 proteins of 
HPV are required for both replication of viral DNA and transcriptional regulation 
[Longworth and Laimins, 2004]. The Long control region (LCR), an 800 bp long 
nonencoding region of HPV genome, contains an epithelial cell-specific enhancer, 
putative binding sites for cellular and viral transcription factors and the P97 promoter at 
its E6-proximal end. The transcription of HPV16 early genes initiates at the p97 early 
promoter and is controlled by a complex interaction of many cellular and viral factors 
that bind to the regulatory region in the LCR. Some of these factors include; YY1,NF1, 
SP1, AP1, TEF1, Oct-1, GRE, and NF-IL6 [Chan et al., 1990; Chong et al., 1991; Ishiji 
et al., 1992; Apt et al., 1994; May et al., 1994; O’Connor and Bernard,1995; Khare et al., 
1997]. P97 activity plays the central role in the pathogenesis of HPV16. Exchange of 
nucleotides within transcription factor binding sites resulting in an increase in viral 
promoter activity and enhanced viral tumorigenesis, has been previously reported for 
HPV16 [Dong et al., 1994; Kammer et al., 2000; Tornesello et al., 2000]. One study 
reported that altered p97 activities are also primarily responsible for the strong 
differences in replication levels in HPV16 LCR variants [Hubert, 2005]. Although almost 
all cases of cervical cancer are attributable to HPV infection, infection alone is not 
sufficient to cause cancer. HPV DNA has often been found in normal cervical tissue 
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[Johnson et al., 1990; Woods et al., 1993]. The rate of HPV infection and cervical cancer 
is highest in the African continent. A previous study investigated the distribution of HPV 
genotypes in a population of Zambians with normal pap smears [Ng’andwe et al., 2007]. 
That study showed that HPV16 and HPV18 were the two most prevalent types, and each 
was present in 21.6% of Zambian samples, significantly higher than the average world 
rate [Ng’andwe et al., 2007]. In the present study, six novel HPV16 variants were 
identified by sequence changes in the LCR. HPV variants were isolated from vaginal 
lavage specimens from Zambian women with normal pap smears. To correlate LCR 
mutations with changes in p97 promoter activity, a luciferase reporter gene was cloned 
under the control of each LCR variant or the LCR of the HPV16 W12E isolate. The 
W12E HPV16 isolate falls within the European group and is widely used as a prototype 
for HPV16 studies since the full-length genome was cloned [Flores et al., 1999]. LCR 
variants that contained multiple mutations were systematically analyzed for the 
contribution of each point mutation to LCR promoter activity. 
 
 
MATERIALS AND METHODS 
Study Participants 
This study reports an analysis of HPV16 variant distribution among HIV positive and 
negative women, sampled from a previously established cohort study [Ng’andwe et al., 
2007]. All Human subjects protocols were approved by safety committees at the 
University of Zambia and UNL in accordance with the Helsinki Declaration. Patient 
participation was entirely voluntary and written consent was required for inclusion in 
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the study. Demographic details of the cohort participants from the metropolitan area of 
Lusaka were collected and disease histories as well as physical examinations were carried 
out to rule out any clinical symptoms or visible signs for these conditions. Pap smears 
were examined and classified according to the pap classification protocol; pap I (normal), 
pap II (inflammation), pap III (dysplasia), pap IV (carcinoma in situ), and Pap V 
(carcinoma), as described previously [Ng’andwe et al., 2007]. All of the participants 
chosen for this study had normal pap smears. 
Sample Collection 
Vaginal lavage samples and pap smears were collected from all patients. Vaginal lavage 
specimens, treated with DNeasy lysis buffer (Qiagen, Valencia, CA) were stored at -
20
0
C. All specimens were then shipped to the Nebraska Center for Virology at the 
University of Nebraska-Lincoln (UNL) for testing. 
DNA Isolation 
Total DNA was extracted from vaginal lavage samples using the DNeasy Tissue 
extraction kit (Qiagen). HPV16 infection in these samples was confirmed by PCR using 
GP5+/GP6+ and CPI/CPII primers followed by sequencing as detailed in the previous 
study [Ng’andwe et al., 2007]. 
 
PCR Amplification of the LCR 
 
The LCR of HPV16 was amplified from the DNA samples by use of one pair of primers: 
P-LCR1: 5’-CCGAGCTCACGCAAAAAACGTAAGCTG-3’ (nt7,133–7,150) with the 
SacI site underlined and P-LCR2: 5’-CCAAGCTTTCCTAGAACATTGCAGTTCTC- 
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3’ (nt 96–114) with the HindIII site underlined. These primers amplified a DNA fragment 
of 886 bp, corresponding to the complete LCR sequence of HPV16 (nt 7,133–114). The 
PCR amplification was performed in 50 ml of the reaction mixture containing 
2 ml template DNA, 1.5 mM MgCl2, 10 mM dNTP,10 pmol of each primer and 5 U of 
Taq polymerase (Invitrogen, San Diego) at the cycle condition of denaturing at 948C for 
50 sec, annealing at 588C for 50 sec, extension at 728C for 1 min, totally 30 cycles. 
PCR products were analyzed on 2% agarose gel and purified with QIAquick Gel 
Extraction Kit (Qiagen), and then sequenced on both strands for the entire LCR of 
HPV16. To ensure that identified LCR sequence variants were not the result of Taq-
derived mis-incorporations, three independent PCR amplifications, cloning, and 
sequencing steps were performed. The sequence data was compared with the 
corresponding fragment of HPV16 W12E isolate by use of BLAST alignment software 
online (http://blast.ncbi.nlm.nih.gov/). 
 
Plasmid Constructions 
The luciferase reporter vector under control of the LCR from HPV16 isolates (pGL3-
LCR) were constructed by cloning the entire LCR from HPV16 variants, as well as the 
W12E isolate into the SacI and HindIII multiple cloning site of pGL3-basic plasmid 
(Promega, MadisonQ3). The generated recombinant plasmids were: pGL3-LCR-101, 
pGL3-LCR-110, pGL3-LCR-902, pGL3-LCR-374, pGL3-LCR-536,pGL3-LCR-434, and 
pGL3-LCR-W12E. The recombinant plasmids to be used in transfection experiments 
were prepared using QIAfilter Plasmid Maxi Kit (Qiagen).The mutant constructs 
containing the individual point mutations that existed in the LCR of 374 and 110 HPV16 
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variants were created using the Quick Change II XL Site-Directed Mutagenesis kit 
(Stratagene, San DiegoQ4). The point mutations were introduced to LCR of HPV16 
W12E isolate by PCR with various primers containing mutation at nt 7,405, nt7,416, nt 
7,632, nt 7,742, nt 7,797 in variant 374, and nt 47, nt 7,405, nt 7,826 in variant 110. The 
parent plasmid was removed by digestion with DpnI, and further transformation was 
carried out according to the manufacturer’s instructions. The mutant recombinant 
plasmids pGL3-374-7405 Mu, pGL3-374-7416 Mu, pGL3-374-7632 Mu, pGL3-374-
7742 Mu, pGL3-374-7797 Mu, pGL3-110-47 Mu, pGL3-110-7826 Mu, and pGL3-374-
7405 Mu were generated. 
 Cell Culture and Transient Transfection 
HeLa cells and HaCat cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum. Cells were seeded at a density of 2 
x10
5
 cells per well of six-well plates 1 day prior to transfection. Two micrograms 
plasmids of pGL3-LCR containing the distinct LCRs from the different HPV16 variants, 
mutated LCRs or W12E LCR prototype were transfected into monolayer cells together 
with 1 mg pCMV-b-galactosidase expression plasmid that served as an internal control to 
normalize for transfection efficiency. The luciferase activity was measured at 48 hr post-
transfection with the Luciferase Assay system (Promega) according to the manufacturer’s 
protocol. The relative light units were determined using a luminometer. The expression of 
b-galactosidase activity was determined using O-nitrophenyl-b-D-galactopyranoside 
(ONPG) as a colorimetric substrate. Relative luciferase activity measurements of the 
different plasmids were normalized against b-galactosidase activity. The averages were 
based on the mean of five independent experiments.  
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RESULTS 
Identification of HPV16 Variants 
A total of 11 HPV16 positive patient samples were recovered in a previous study 
[Ng’andwe et al., 2007]. DNA fragments containing the HPV16 LCR (nt 7,133–114) 
were amplified from HPV16 positive vaginal lavage specimens of Zambian women who 
had normal pap smears. We searched for genetic variation in the LCRs from the 11 
HPV16 positive samples by DNA sequencing. Five wild-type (European) HPV16 LCRs 
and six novel HPV16 variants were recovered with nucleotide changes in the LCR 
sequence, not previously described (Table 4.1). Five new variants; 902,110, 374, 434, 
and 536 were classified within the European group and they exhibited 2, 4, 6, 1 and 3 
intra-type variations, respectively, compared to HPV16 W12E isolates. The rate of 
mutation that accounts for 902, 110, 374, 434, and 536 variants in LCR appears to be 
above the intrinsic cellular mutation rate. Only one variant, 101, classified as African 
group, differed by two nucleotides, at nt 7,416 and nt 7,797, from the sequence of the 
Af1a B2 isolate published by Kammer et al. [2000]. The G to A transition at nt 7,797 was 
found in all variants except for variant 902. In contrast to nucleotide substitutions in the 
LCR of HPV variants described previously, several nucleotide insertions were found 
within LCR sequence of new HPV16 variants identified in this study. These data suggest 
that the diversity of HPV variants in natural infections has been underappreciated. 
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Two HPV16 Variants Isolated From Zambian Women Have Relatively Lower 
Promoter Activities 
In order to assess the influence of nucleotide alterations in LCR on promoter activity, we 
utilized the recombinant luciferase reporter plasmids containing distinct LCR sequences 
from six isolated HPV16 variants, as well as the HPV16 W12E isolate, each cloned 
upstream of a luciferase reporter gene (pGL3). Constructs were transiently transfected 
into HeLa and HaCat cells. The luciferase assay revealed that there were no significant 
differences in promoter activity of LCRs from 902, 101, 434, and 536 variants compared 
to that of HPV16 W12E prototype isolate. 
TABLE 4.1. Nucleotide Mutations Identified in the LCRs of the HPV16 Variants. 
Nucleotide changes are indicated within each variant. Insertions are indicated by 
(In) and deletions by (Del). Predicted transcription factor binding sites ‘‘BS’’ are 
shown in the right-most column. 
 
 
However, the expression of luciferase under control of LCR from variants 110 and 374 
decreased to 30% and 26.6% of that from W12E isolate in HeLa cells, and decreased to 
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27% and 34% in HaCat cells (Fig. 4.1). These data suggest that variation in LCR-p97 
promoter function are tolerable and potentially important for HPV fitness. Previous 
studies have found that mutations in the LCR that alter p97 promoter function often 
significantly affect gene expression as well as viral copy number [Hubert, 2005]. 
 
Fig. 4.1. The promoter activity under control of LCR from different variants as well 
as the W12E isolate is shown. HeLa cells and HaCat cells were transfected with 2 
mg pGL3-LCR plasmids containing LCR of HPV16 W12E or different variants. 
The relative luciferase activity was averaged from five independent experiments in 
HeLa, HaCat cells and presented relative to that of W12E pGL3-LCR. The data are 
represented as the mean ±SD, indicated by error bars. 
 
 
The Contribution of Different Point Mutations in LCR of HPV16 Variants 374 and 
110 on Decreased Promoter Activities 
To determine which of these point mutations in the LCR of HPV16 variants 374 and 110 
decreased promoter activity of the virus, we introduced each different point mutation 
independently in LCR using the backbone of pGL3-LCR-W12E plasmid. The mutated 
plasmids were transfected into HeLa cells for analysis. The results showed that in the 
variant 374,the expression of luciferase under control of the mutated LCR with mutations 
at nt 7,405, nt 7,416, nt 7,632, and nt 7,797 were little compared to the plasmid with LCR 
from the W12E isolate. The plasmid containing the mutation at nt 7,742 was responsible 
40 
 
for a 70% reduction in the expression of luciferase (Fig. 4.2), corresponding to the 
expression level of luciferase under the control of LCR from variant 374 with all five 
point mutations. These results show that decreased promoter activity of variant 374 was 
primarily attributed to the point mutations at nt 7,742. In Electrophoretic mobility shift 
assay (EMSA) no difference was found in the binding of nuclear extracts prepared from 
HeLa cells with two probes (from nt 7,733 to nt 7,750) designed from HPV16 W12E and 
variant 374 (data not shown), yet the changes could still be affecting transcriptional 
activation. In the variant 110, the expression of luciferase under the control of the LCR 
with mutations at nt 7,405 decreased by about 87.5% and a mutation at nt 7,826 
decreased to about 45%. The decrease in promoter activity in variant 110 maybe due to a 
synergistic effect between the two point mutations that existed in it. The mutation at nt 
7,405 and nt 7,826 also did not induce an obvious difference in the binding affinity 
between nuclear extracts and DNA in EMSA results (data not shown). 
 
Fig. 4.2. The contribution of different point mutations found within the LCR of 374 
or 110 variants on promoter activity compared to the W12E isolate. HeLa cells were 
transfected with 2 mg pGL3-LCR  plasmids containing the LCR of HPV16 W12E or 
each combination of different point mutations from 374 or 110 variants respectively. 
The relative luciferase activity is the average of five independent experiments in 
HeLa cells and presented relative to that of W12E pGL3-LCR. Data are represented 
as the mean ±SD, indicated by the error bars. 
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DISCUSSION 
In this study we identified novel HPV16 LCR sequence variants from cervico-vaginal 
lavage specimens isolated from Zambian women who had no evidence of HPV infection. 
Analysis of the LCR nucleotide sequences showed that five of six HPV16 variants were 
classified within the European group, while the other one, variant 101, was classified in 
the African group. Most studies on HPV16 variants have focused on isolates from clinical 
patients who already had cervical cancer or cervical squamous intraepithelial lesions 
(SIL). In contrast, the present study brings evidence of a significant number of LCR 
variant strains of HPV16 actively replicating in asymptomatic Zambian women. We 
focused on variants of the HPV16 LCR in this study since the p97 promoter has a crucial 
role in regulating transcription and replication of the virus. Although the direct biological 
consequence of variation in the LCR of HPV genomes on cervical carcinogenesis is not 
fully understood, several studies indicate that variants of HPV16 are associated with 
higher-risk of cervical neoplasias of various stages [Smits et al., 1994; Londesborough et 
al., 1996; Tornesello et al., 2000; Hildesheim et al., 2001; Burk et al., 2003; Hubert, 
2005; Schlecht et al., 2005; Pande et al., 2008]. The mutations accrued in HPV genomes 
isolated from tumors are diverse in location and type, and thus the functional outcome is 
difficult to predictable. However, our current evidence of multiple mutations in the LCRs 
of actively replicating HPV16 genomes from women with normal pap-smears suggests 
that these differences are relevant to viral promoter activity and fitness. Relatively few 
studies have been done on HPV variants from women with normal pap-smears [Schmidt 
et al., 2001]. Non-European variants, particularly the Asian- American variants, tend to 
persist more frequently than E variants. In addition, non-E variants were more strongly 
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associated with both the prevalence and incidence of high-grade cervical intraepithelial 
neoplasia (CIN) lesions and cervical cancer than the E variants [Villa et al., 2000]. 
Kammer et al. [2000] reported that HPV16 Af1a and 2a variants exhibit p97 promoter 
activity comparable to the European reference clone. Thus, it may not be that surprising 
that HPV E and Af1a variants are found in women with normal Pap smears. It is possible 
that the distribution of variants is not only influenced by geographical region but also by 
severity of clinical phenotype. The results showed that six HPV16 LCR variants 
exhibited differing p97 promoter activity when linked upstream of the luciferase reporter 
gene. The 374 and 110 variants showed approximately a 70% decrease in p97 promoter 
activity, whereas other E group variants in this study and Af1a group, 101 variant were 
more or less as active as the HPV16 W12E promoter. This kind of large decrease in p97 
promoter activity observed in variants 374 and 110, although rarely reported, might favor 
low-copy and long-term persistence of the virus, a reduced probability of cervical cancer. 
The importance of the transcription factor binding sites within LCR for transcription and 
expression of HPV16 early genes has been confirmed in previous studies [Hubert, 2005]. 
Single nucleotide changes can increase or decrease transcription factor affinity for 
binding sites or change their ability to interact with accessory proteins. Schmidt et al. 
[2001] reported that HPV16 LCR variants isolated from cancer cells contain nucleotide 
changes predominantly within or close to YY1 binding site. Variants obtained from 
asymptomatic carriers contained different single nucleotide changes, mainly within or 
close to binding sites of transcription factors such as AP-1, Oct-1, NF-1, TEF-1, TEF-2, 
SP1, viral E2, and also YY1 [Schmidt et al.,2001]. Not surprisingly, the results showed 
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that some of the nucleotide exchanges identified in LCR from the six different HPV16 
variants were located near or within putative binding site for cellular or viral factors. 
The binding sites in the LCR variants 374 and 110 that resulted in a significant decrease 
in p97 promoter activity included AP1, NF-1, YY-1, TEF-1, and E2 binding sites (Fig. 
4.3). 
 
Fig. 4.3. Map of the putative transcription factor binding sites within LCR of 
HPV16. Each of the transcription factor binding sites are indicated; AP-2, AP-1, 
YY1, HPV16 E2, TEF1, NF-1, Sp1, and Oct-1. 
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 By systematic analysis of point mutations, we identified the important nucleotide 
changes in variants 374 and 110 by their effects on p97 promoter activity. Only the LCR 
with nucleotide exchanges in the NF-1 binding site, a G insert at nt 7,742 and an A insert 
at nt 7,744, led to a decrease in p97 promoter activity to a level corresponding to that of 
374 variant. These results indicate that the decreased p97 promoter activity of variant 374 
was mainly attributed to affects on the NF-1 binding site near nt 7,742. As a ubiquitously 
expressed transcription factor, NF-1 binds to the regulatory elements within the LCR and 
plays a key role in the transcriptional stimulation of E6/E7 expression through the p97 
promoter in HPV [Chong et al., 1991; Apt et al., 1994]. The nucleotide changes at NF-1 
binding site that existed in LCR of variant 374 probably reduce the binding affinity 
between NF-1 and DNA sequence, thus partly decreasing the transcriptional activity 
through NF-1. However, the EMSA with HeLa cell nuclear extract was not able to detect 
differences in protein binding to oligonucleotides with or without mutations at nt 7,742 
(as in variant 374 (data not shown)). In variant 110, a point mutation at nt 7,826 
(corresponding to YY1 and TEF-1 binding sites) led to a major decrease in promoter 
activity. YY1 is considered a repressor for HPV16 transcription activity, and several YY1 
binding sites have been reported in the HPV16 LCR. Single nucleotide mutations in 
YY1-binding sites that increase p97 activity three- to six fold have been identified in 
HPV 16 DNA from cervical carcinomas [Dong and Pfister, 1999]. In this study, we found 
a mutation at nt 7,826, within the YY1 binding site, which decreased p97 activity by 
about 50%. The YY1 binding site at nt 7,826 overlaps with the TEF-1 binding site. This 
may indicate competition for binding, displacement, or steric hindrance between the two 
proteins. We found it intriguing that there were a significant number of HPV16 variants 
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circulating in naturally occurring infections. The present results suggest that HPVs may 
exist in greater evolutionary diversity than previously appreciated. APOBEC3 cytosine 
deaminases have been described for their role in restricting infectivity of retroviruses by 
editing the single stranded DNA. Interestingly, a previous study has also shown that these 
deaminases are able to edit HPV 16 DNA [Vartanian et al., 2008]. Furthermore, 
APOBEC3 expression is known to be induced in the more terminally differentiated 
keratinocyte layers, where HPV genome amplification takes place. One of the variants we 
isolated, 101 did not show decreased promoter activity, but had point mutations typical of 
those induced by APOBEC 3a, 3c, and 3H [Vartanian et al., 2008]. This variant fell 
within the Africa group, which is thought to be less oncogenic compared to the European 
group. It is possible that at least some of this variation in HPV genomes is induced by 
mechanisms such as that described for APOBEC3 cytosine deaminases, but other 
mechanisms, such as polymerase driven insertions and deletions clearly also impact the 
pool of variants. 
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GENERAL CONCLUSIONS 
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The purpose of this study was to look at the effect of the two variables; HIV and genital 
lesions on HPV concordance  within heterosexual couples. We also wanted to analyze  
HPV 16 sequence variations in the L1 and LCR regions to determine  the prevalence and 
novelty of HPV 16 variants. Understanding   the effects of  HIV and genital lesions on 
HPV concordance within couples and the knowledge of the circulating  HPV 16 variants  
in the population will help in designing prevention strategies. 
Though the study sample was small, we found evidence   of HPV  concordance within 
couples. The results also showed the mean age typical  for men and women presenting 
with cervical  and penile lesions. A previous study  in Zambia has shown that there is a 
high prevalence of oncogenic HPV strains  compared to elsewhere, and in this study  
most of the infections were attributed to HPV 16 and this means there is increased risk 
for premalignant and  malignant lesions. This is indeed supported by a higher proportion 
of cervical lesions in this study cohort. Presence of  genital lesions correlate with  HPV 
concordance within partners, but we also found that individuals without lesions can still 
harbor same HPV types with their partners. However use of preventive strategies like 
male circumcision which has been shown to reduce penile lesions may be helpful in 
reducing this effect. 
Several studies have found that HPV infection is highly associated with HIV positivity 
and we confirmed that with our results and a study before this one. In  Zambia like other 
countries in Sub Saharan Africa, HPV infection is high in the general population and 
even higher in HIV infected individuals. The uptake of HIV testing in our cohort   was  
82 % much higher than the  national average uptake of  only about 10%.This was 
possibly due to the intense counseling and the fact that couples were already in the 
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clinical setting with a disease which may have motivated them to agree to HIV testing. 
The HIV prevalence was very high, however, the coinfection with HPV and possible 
ulcerative lesions  could indicate both high risk behavior and potentiation of HIV 
infection or simply due to   a selection of a population with much higher risk of infection. 
However due to small sample size we could not establish the correlation between  HIV  
positivity and  HPV concordance within partners.  
The HPV genotype distribution differs by  region, and HPV 16 has been found to be the 
most common of all genotypes globally with HPV 16 variants isolated from clinical 
samples. The defining character of  HPV 16 variants is the difference in their 
oncogenicity  and  distribution by geographical region and it is possible that the 
distribution of HLA alleles in the population might influence this difference. We 
observed that  HPV 16 variants are more prevalent in natural infections than previously 
perceived .We isolated L1 variants from the two African groups,  and the European group  
as well as  six  novel HPV 16 variants with nucleotide exchanges in the LCR region. Five 
were classified as the HPV 16 variant European group, and one as the African group. 
Two of these variants had relatively lower promoter activity, 30% of that of the wild type 
strain. The decreased promoter activity of some HPV 16 variants decrease expression of 
viral oncogenes and may be linked with the development, phenotype and prognosis of the 
cervical lesions in women infected with these kinds of HPV 16 variants. 
Our findings in this study provide additional information and give us more insight into 
the diversity of HPV 16 in   the general population. We have also  shown the use of 
variant analysis as a tool that can be used to trace genotype concordance within couples 
with more  a higher accuracy. HPV variant data is important in developing  vaccines and 
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other therapeutic approaches to control  disease progression.  Novel antiviral therapeutics 
that interfere with viral assembly and entry into cells would inhibit  establishment of a 
persistent infection thereby preventing progression of tumorigenesis. 
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